September 09, 2026

FDA expands sevabertinib approval in NSCLC

SOHO-01 data showed a 75% confirmed objective response rate among 69 patients without previous systemic therapy.

MDSpire News

September 03, 2026

AI cuts lesion measurement time by 34%

Automated lesion measurements increased agreement on treatment response, although expert-generated proposals were accepted more often and required fewer adjustments.

MDSpire News

September 01, 2026

Tele-guided lung ultrasound may be acceptable to paramedics

Trainees rated remote-guided imaging favorably, while technical reliability and communication emerged as barriers to implementation.

MDSpire News

August 28, 2026

FDA monthly preview: Key September decisions to watch

Several FDA decisions across multiple specialties are expected this month.

MDSpire News

August 26, 2026

Radiologists may misidentify AI images

CT and MRI images were harder to distinguish than radiographs and ultrasound, while subspecialty expertise was associated with greater accuracy.

MDSpire News

August 24, 2026

Image conditioning may lower AI detectability

Radiologists identified fewer synthetic chest radiographs when generative models used normal radiographs as conditioning images, while side-by-side comparison improved detection.

MDSpire News

August 05, 2026

AI-Assisted MRI Method May Rival CT in Lung Nodule Detection

A rapid AI‐assisted imaging protocol detected nearly all clinically relevant solid lung nodules while closely matching CT for suspicious screening classifications.

MDSpire News

July 23, 2026

FDA Approves Zidesamtinib for ROS1 Lung Cancer

Phase 1/2 ARROS-1 data showed a 44% objective response rate, with most responses ongoing at 6 months.

MDSpire News

July 23, 2026

Conservative Management May Be Safe for Small Mediastinal Lesions

Most anterior mediastinal lesions smaller than 3 cm remained stable during annual computed tomography surveillance, supporting a conservative management strategy for selected patients in lung cancer screening.

MDSpire News

July 17, 2026

FDA Approves New Iohexol Vials

The approval includes additional 300 mg iodine/mL and 350 mg iodine/mL vial presentations.

MDSpire News